Jerusalem factory for Universal Flu vaccine

Israeli biotech Biondvax is to receive a Government grant for 20% of the NIS 20 million required to build a Jerusalem factory for commercial scale production of its M-001 Universal Flu vaccine.  Biondvax plans to produce tens of millions of doses of M-001 annually, including for Phase 3 trials.

http://www.biondvax.com/2017/03/biondvax-approved-for-grant-from-israels-ministry-of-economy-and-industry-to-build-facility-for-commercial-scale-production-of-its-universal-flu-vaccine/

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *